Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2376 - 2400 of 14963 in total
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Description: … ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable,...
Approved
Investigational
Matched Description: … binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Approved
Investigational
Matched Description: … and chromatography steps. ... The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin ... The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Approved
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been …
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Iupac: … (64),9,11,14,16,23,25,27(61),29,31,33(60),41,43,45(57),46(51),47,49,62,65-henicosaene-52-carboxylic acid
Matched Description: … antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and ... All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and ... Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Matched Description: … , and mixed symptoms of depression and anxiety or agitation. ... Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression ... TCAs are potent inhibitors of serotonin and norepinephrine reuptake. …
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing...
Approved
Withdrawn
Matched Description: … It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. ... The drug produces significant coronary vasodilation and modest peripheral effects. …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …
An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Approved
Matched Description: … It also acts as a chemosterilant for male houseflies and other insects. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tyloxapol is a non-ionic detergent often used as a surfactant.
Approved
Investigational
Matched Categories: … Cough and Cold Preparations …
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and ... Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Description: … Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. …
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than air. It is toxic to hemoglobin utilizing animals (including humans), when encountered in concentrations above about 35 ppm, although it is also formed in normal animal metabolism in low quantities, and is thought...
Approved
Investigational
Matched Description: … inflammatory diseases of the lung and other organs. ... The DLCO test is both convenient and simple for the patient to undergo. ... Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than …
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Approved
Investigational
Matched Description: … neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March ... Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical ... L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and
Matched Categories: … Sex Hormones and Insulins …
Approved
Experimental
Investigational
Matched Categories: … Alimentary Tract and Metabolism …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …
Displaying drugs 2376 - 2400 of 14963 in total